lenalidomide

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

lenalidomide

Trade Name(s):

Revlimid

NCI Definition [1]:

A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.

Biomarker-Directed Therapies

Lenalidomide can be used in the treatment of myelodysplastic syndromes. del(5)(q31q33), TP53, and TP53 Frameshift are the most frequent biomarker inclusion criteria for use of lenalidomide [2].

Myelodysplastic Syndromes +

Disease is predicted to be sensitive to lenalidomide: -

Biomarker Criteria:

Sample must match all of the following:

del(5)(q31q33)

Clinical Setting(s): First Line of Therapy (NICE, BNF, SMC)

Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Biomarker Criteria: Sample must match all of the following: del(5)(q31q33)	Clinical Setting(s): First Line of Therapy (NICE, BNF, SMC)
	Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Disease is predicted to be resistant to lenalidomide: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

TP53 Frameshift, Nonsense, or Missesense Mutations

Sample must match all of the following:

del(5)(q31q33)

Clinical Setting(s): First Line of Therapy (NCCN)

Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Biomarker Criteria: Sample must match all of the following: Sample must match one or more of the following: TP53 Frameshift, Nonsense, or Missesense Mutations Sample must match all of the following: del(5)(q31q33)	Clinical Setting(s): First Line of Therapy (NCCN)
	Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Biomarker Criteria:

Sample must match all of the following:

del(17)(p13), del(5)(q31q33)

Clinical Setting(s): First Line of Therapy (NCCN)

Biomarker Criteria:

Sample must match all of the following:

del(17)(p13), del(5)(q31q33)

Clinical Setting(s): First Line of Therapy (NCCN)

Biomarker Criteria:

Sample must match all of the following:

del(5)(q31q33)

Sample must match one or more of the following:

TP53 Frameshift, Nonsense, or Missesense Mutations

Clinical Setting(s): First Line of Therapy (BNF)

Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Biomarker Criteria: Sample must match all of the following: Sample must match all of the following: del(5)(q31q33) Sample must match one or more of the following: TP53 Frameshift, Nonsense, or Missesense Mutations	Clinical Setting(s): First Line of Therapy (BNF)
	Note: Indicated for Myelodysplastic Syndromes (MDS) with isolated del (5)(q31q33). Secondary mutations in TP53 however, can lead to diminished response or relapse after treatment with lenalidomide.

Clinical Trials

View Clinical Trials for lenalidomide

Lenalidomide has been investigated in 159 clinical trials, of which 142 are open and 17 are closed. Of the trials investigating lenalidomide, 1 is early phase 1 (1 open), 43 are phase 1 (35 open), 26 are phase 1/phase 2 (22 open), 62 are phase 2 (58 open), 24 are phase 3 (23 open), 1 is phase 4 (1 open), and 2 are no phase specified (2 open).

del(17)(p10), MS4A1 Expression, and IGH-FGFR3 Fusion are the most frequent biomarker inclusion criteria for lenalidomide clinical trials.

Multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma are the most common diseases being investigated in lenalidomide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lenalidomide

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lenalidomide

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lenalidomide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

cc-5013, cdc 501, Revlimid, lenalidomide, lenalidomide [chemical/ingredient], cc 5013, imid-1, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, lenalidomide (product), imid3 cpd, lenalidomide, imid-1, celgene brand of lenalidomide, cc5013, lenalidomide (substance), 3-(4-amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione, 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2h- isoindol-2-yl)-, imid3, revimid, 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Drug Target(s) [2]:

CRBN

NCIT ID [1]:

C2668

SNOMED ID [1]:

C-781E9

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Biomarker-Directed Therapies

Clinical Trials

Drug Details

References

About

Molecular Medicine

Content Types